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Abstract: OBJECTIVES Disc diffusion is still largely based on manual procedures. Technical varia-
tions originate from inoculum preparation, variations in materials, individual operator plate streaking
and reading accuracy. Resulting measurement imprecision contributes to categorization errors. Biologi-
cal variation resembles the natural fluctuation of a measured parameter such as antibiotic susceptibility
around a mean value. It is deemed to originate from factors such as genetic background or metabolic
state. This study analysed the relative contribution of different technical and biological factors to total
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mathematical model was developed to analyse the individual error factor contribution to disc diffusion
variation for each of the tested drug-species combinations. RESULTS The contribution of biological
variation to total diameter variance ranged from 10.4% to 98.8% for different drug-species combinations.
Highest biological variation was found for Enterococcus faecalis WT and vancomycin (98.8%) and for
penicillinase-producing Staphylococcus aureus and penicillin G (96.0%). Average imprecision of auto-
mated zone reading revealed that 1.4%-5.3% of total imprecision was due to technical variation, while
materials, i.e. antibiotic discs and agar plates, contributed between 2.6% and 3.9%. Inoculum preparation
and manual plate streaking contributed 6.8%-24.8% and 6.6%-24.3%, respectively, to total imprecision.
CONCLUSIONS This study illustrates the relative contributions of technical factors that account for a
significant part of total variance in disc diffusion. The highest relative contribution originated from the
operator, i.e. manual inoculum preparation and plate streaking. Further standardization of inoculum
preparation and plate streaking by automation could potentially increase the precision of disc diffusion
and improve the correlation of susceptibility reports with clinical outcome.
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Objectives: Disc diffusion is still largely based on manual procedures. Technical variations originate from inocu-
lum preparation, variations in materials, individual operator plate streaking and reading accuracy. Resulting
measurement imprecision contributes to categorization errors. Biological variation resembles the natural fluctu-
ation of a measured parameter such as antibiotic susceptibility around a mean value. It is deemed to originate
from factors such as genetic background or metabolic state. This study analysed the relative contribution of
different technical and biological factors to total disc diffusion variation.
Methods: For calculation of relative error factor contribution to disc diffusion variability, five experiments were
designed keeping different combinations of error factors constant. A mathematical model was developed to
analyse the individual error factor contribution to disc diffusion variation for each of the tested drug–species
combinations.
Results: The contribution of biological variation to total diameter variance ranged from 10.4% to 98.8% for
different drug–species combinations. Highest biological variation was found for Enterococcus faecalis WT and
vancomycin (98.8%) and for penicillinase-producing Staphylococcus aureus and penicillin G (96.0%). Average
imprecision of automated zone reading revealed that 1.4%–5.3% of total imprecision was due to technical
variation, while materials, i.e. antibiotic discs and agar plates, contributed between 2.6% and 3.9%. Inoculum
preparation and manual plate streaking contributed 6.8%–24.8% and 6.6%–24.3%, respectively, to total
imprecision.
Conclusions: This study illustrates the relative contributions of technical factors that account for a significant part
of total variance in disc diffusion. The highest relative contribution originated from the operator, i.e. manual
inoculum preparation and plate streaking. Further standardization of inoculum preparation and plate streaking
by automation could potentially increase the precision of disc diffusion and improve the correlation of
susceptibility reports with clinical outcome.
Introduction
Disc diffusion is one of the mainstay methods for antimicrobial
susceptibility testing (AST). However, in contrast to the recent
advances in microbial identification by the introduction of nucleic
acid amplification techniques and MALDI-TOF MS into the clinical
laboratory, the prospects of improved AST are considered less
predictable.1
Disc diffusion is still largely based on manual procedures for
preparation and reading of agar plates and zone diameters.
Technical variations of disc diffusion AST thus originate from
both operator-dependent factors, i.e. inoculum preparation, plate
streaking or reading precision, and operator-independent variations
in materials, e.g. agar plates and antibiotic discs, or incubation
conditions.2–4 Technical variation significantly contributes to cat-
egorization errors and, thus, erroneous treatment of patients.5–7
Many attempts were made to further standardize disc diffusion
testing in the 1960s and 1970s, mainly focusing on standardizing
basic parameters such as agar type, agar depth, disc content, time
of pre-diffusion, atmospheric conditions, the reading endpoint or
the ideal inoculum density.2,3 Current EUCAST and CLSI guidelines
for AST are essentially based on these early studies and describe
a structured and standardizedmethodology.8,9 In addition to tech-
nical variations, zone diameter distribution variations also comprise
individual strain variations, i.e. the biological diversity of a species
and/or genotype, respectively.7 This biological variation appears
as random fluctuations in zone diameter values around a mean,
which usually produce a Gaussian distribution.
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Automation of laboratory procedures is of increasing import-
ance for clinical microbiology laboratories as it is regarded as
essential for further standardization ofmicrobiological techniques
with respect to higher quality, more rapid availability and
improved reproducibility of results.10–12 However, scientific litera-
ture systematically analysing the impact of automation on the
quality of microbiological results is rare.13 Automation of zone
diameter reading has already been shown to increase the preci-
sion and reproducibility of disc diffusion AST.14 Other technical
variables may similarly be standardized by automation to
improve the reliability and reproducibility of disc diffusion and
the resulting clinical susceptibility categorizations and treatment
recommendations.
To quantify the relative contribution of different technical fac-
tors to the total variation of the disc diffusion method, we ana-
lysed the contribution of technical and biological factors to the
overall zone diameter variation in disc diffusion AST to provide a
basis for targeting the most promising technical aspects for fur-
ther standardization. Technical variables analysed were: (i) zone
diameter reading; (ii) materials (i.e. agar plates, antibiotic discs,
swabs); (iii) inoculum preparation; and (iv) inoculation of AST
agar plates.
Methods
Relative contribution of variables and experimental
designs
For the calculation of the relative contribution of individual factors (Table 2)
to the total inaccuracy of disc diffusion AST, the following experiments
(A–E) were designed, each of which had a different combination of error
factors that were kept constant or left variable. The resulting matrix is
shown in Figure 1. Experiments A–Ewere arranged according to increasing
complexity of variable factors. In detail, Experiments A–E were carried out
as follows.
Experiment A
One hundred repeat zone diameter measurements were made of the
same inhibition zone on the same Mueller–Hinton agar plate of EUCAST
quality control strains using the Sirscan automated zone reader (i2a,
Montpellier, France).
Experiment B
One hundred repeat zone diametermeasurements weremade for EUCAST
quality control strains of 100 individual inocula (0.5 McFarland standard)
prepared from 100 individual colonies picked from the same agar plate
by the same operator using the same lot of antibiotic discs and the
same lot of Mueller–Hinton agar plates, eliminating inter-operator vari-
ance in plate streaking. All zone diameters were recorded using the
Sirscan automated zone reader.
Experiment C
One hundred repeat zone diametermeasurements weremade for EUCAST
quality control strains from 100 individual Mueller–Hinton agar plates
prepared from the same inoculum (0.5 McFarland standard) streaked by
10 different operators (10 plates for each operator) using the same lot
of antibiotic discs and the same lot of Mueller–Hinton agar plates, using
the Sirscan automated zone reader.
Experiment D
We measured n zone diameter measurements for EUCAST quality control
strains from the internal quality control of the clinical microbiology labora-
tory of the Institute of Medical Microbiology, University of Zurich over a











A Variable Constant Constant Constant Constant
B Variable Variable Variable Constant Constant
C Variable Variable Constant Variable Constant
D Variable Variable Variable Variable Constant





Figure 1. Design matrix of experiments A–E according to variation factors. aThe plate-streaking variation factor refers to inter-operator variation.
Intra-operator variations cannot be eliminated.
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zone reader. Individual drug–strain combinations show different numbers
as the composition of the AST panels varied. Exact numbers can be
retrieved from Table 1. Production lots of Mueller–Hinton agar plates
and antibiotic discs as well as inoculum preparation and operators who
performed streaking of AST plates were variable.
Experiment E
We used n zone diameter measurements of n individual clinical strains
using the Sirscan automated zone reader as the reference populations
that were defined above. Strains, Mueller–Hinton agar plates, antibiotic
discs, inoculum preparation and operators were always different.
Bacterial strains
For experiments A, B, C and D we used EUCAST reference strains
Staphylococcus aureus ATCC 29213, Escherichia coli ATCC 25922,
Enterococcus faecalis ATCC 29212 and Pseudomonas aeruginosa ATCC
27853 (for the specific experimental designs see the ‘Relative contribution
of variables and experimental designs’ section). Reference populations of
Experiment Ewere derived from non-duplicate clinical strains isolated over
a 4 year period from2010 to 2014 in the clinicalmicrobiology laboratory of
the Institute of Medical Microbiology, University of Zurich. Isolates of the
same species were considered duplicate(s) if they: (i) originated from the
same patient; and (ii) showed onemajor AND twominor differences in AST
interpretation at a maximum. All duplicates were excluded from the ana-
lysis. The numbers of drug–species combinations are available in Table 1.
Phenotype definitions and reference populations
The WT was defined as all isolates of a given species that are devoid of an
acquired resistance mechanism to the drug analysed. The biological vari-
ation of the WTwas calculated for each drug–species combination separ-
ately. In the case of S. aureus and penicillin G the EUCAST reference strain
(ATCC 29213) used for Experiments A, B, C and D is penicillinase positive
and PBP2a negative. Therefore, the reference population comprised
those non-WT isolates that harboured a penicillinase but were devoid of
PBP2a. Thus, the biological variation of S. aureus and penicillin G was cal-
culated for the penicillinase-positive non-WT population.
WT populations of Experiment E were defined using EUCASTepidemio-
logical cut-offs (ECOFFs) with the exception of the tetracycline’s WT popu-
lations, for which CLSI 2015 clinical breakpoints (CBPs) were used as
EUCAST ECOFFs were not available. The S. aureus penicillinase-positive ref-
erence population comprised isolates that were penicillin G resistant PLUS
isolates that were penicillin G susceptible AND showed a sharp penicillin G
zone edge AND were cefoxitin susceptible applying EUCAST 2014 CBPs.
Susceptibility testing
For susceptibility testing, the disc (i2a, Montpellier, France) diffusion
method was carried out using Mueller–Hinton agar (Becton Dickinson,
Franklin Lakes, NJ, USA) and a 0.5 McFarland standard dilution from over-
night cultures as an inoculum followed by incubation at 358C for 16–18 h
according to EUCAST recommendations.15 McFarland standard dilutions
were prepared by visual comparison of the test tubeswith freshly prepared
and vortexed 0.5 McFarland turbidity standards manufactured according
to EUCAST guidelines, and double-checked using a calibrated Densicheck
instrument (bioMérieux, Marcy-l’Étoile, France) calibrated and used
according to the recommendations of the manufacturer.
Statistical model
Measured disc diameters are random; they scatter around a mean with a
certain standard deviation. Changing any experimental conditions, i.e.
factors, possibly implies a change in mean and standard deviation,
hence the distribution of disc diameters may be shifted and/or stretched.
The experimental setup outlined above does not allow deconvolution of
the individual effects of all the factors.
For each experiment the result of each measurement was decom-
posed additively using the different factors. For the fixed components of
each experiment their contribution was given by a simple offset, i.e. a
fixed effect. For those components that varied between measurements
we considered a random contribution, i.e. a random effect.
For example, for Experiment Awe had only one random effect for read-
ing imprecision. For Experiment E, five random effects were used (reading
imprecision, material variation, inoculum preparation, plate streaking and
biological variation) (Figure 1).
Biological variation always referred to a specific phenotype of a given
drug–species combination, e.g. the WT population or a specific non-WT
population.
For each of the five experiments we estimated the mean and variance
of the disc diametermeasurements. These five estimated variances deter-
mined the variances of the five random effects. We hence had five equa-
tions and five unknowns leading to a unique solution. Unfortunately it
could contain negative values, which are not admissible for variances. To
get at least an approximate solution in each case,we implemented a prag-
matic approach. Whenever one element of the solution was negative we
set it to zero, i.e. the factor had negligible variability. The procedure was
equivalent to minimizing the sum of squared differences between the
original and approximate solutions.
Software
Disc diameter data collected by the Sirscan device were electronically
archived using SIRweb software v100.32 (i2a, Montpellier, France).
Statistical analyses were performed in the ‘R’ programming language
version 3.0.2, which is freely available at http://www.r-project.org/.
Results
Statistical parameters of variation (variance, standard deviation
and the coefficient of variation) increased from Experiment A to
Experiment E, i.e. with increasing number of variables (Table 1
and Figure 2). Median diameters and standard deviations of
Experiment D closely matched EUCAST quality control target
values and accepted quality control diameter ranges (Table 1
and Figure 2). The average coefficient of variation for Experiment A
was 1.5% for all species except for S. aureus (2.3%). Variances,
standard deviations and coefficients of variation for Experiments
B, C and Dwere similar for all species investigated, whereas variance
in Experiment E was particularly high in P. aeruginosa (12.7 mm2;
Table 1).
With respect to individual drug–species combinations, bio-
logical variation contributed to a variable extent to total diameter
variance, ranging from 10.4% to 98.8% in WT ATCC strains
(Table 2). Considering the average of all drug–species combina-
tions, biological variation was highest in P. aeruginosa (81.3%) fol-
lowed by S. aureus (64.0%), E. coli (53.9%) and E. faecalis (47.0%).
Antibiotic classes did not behave uniformly and relative biological
variation for individual drug classes was species-dependent, e.g.
average biological contribution for aminoglycoside measurement
variation was 82.4% for S. aureus and P. aeruginosa, but 23.9% for
E. coli. For the latter species and aminoglycosides, operator
dependence (i.e. plate streaking) was the most significant error
factor (40.2%; Table 2). In contrast, average biological contribu-
tion for fluoroquinolone measurement variation was 49.3% and
Biological variation and technical variables of disc diffusion
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Table 1. Basic summary statistics and EUCAST QC ranges/targets of experiments A–E
Drug





















































































































































































































































































































































Penicillin G A 100 17 0.1 0.3 1.9
B 100 16 1.0 1.0 6.2
C 100 17 1.4 1.2 6.8
D 201 15 1.2 1.1 7.3 12–18 15
E 881 13 33.6 5.8 40.9
Ampicillin A 100 20 0.04 0.2 1.2 A 100 17 0 0.1 0.8
B 100 20 0.8 0.9 4.3 B 100 18 0.9 0.9 5.2
C 100 20 1.4 1.2 5.8 C 100 19 1.7 1.3 7.1
D 117 20 2.6 1.6 8 16–22 19 D 108 18 2.1 1.5 8.0 15–21 18
E 1389 21 7.8 2.8 13.4 E 2779 18 7.5 2.7 15.5
Amoxicillin/clavulanic acid A 100 24 0.3 0.5 2.1
B 100 23 0.8 0.9 3.8
C 100 24 1.0 1.0 4.1
D 117 22 2.0 1.4 6.4 18–24 21
E 4778 24 5.8 2.4 10.2
Piperacillin/tazobactam A 100 22 0.01 0.1 0.5 A 100 25 0.4 0.6 2.5
B 100 24 0.6 0.8 3.4 B 100 27 1.0 1.0 3.8
C 100 24 1.0 1.0 4 C 100 27 1.0 1.0 3.7
D 117 23 2.6 1.6 6.8 21–27 24 D 134 26 2.3 1.5 6.0 23–29 26
E 4773 26 7.8 2.8 11.0 E 2694 24 13.6 3.7 14.9
Cefalotin A 100 21 0 0 0
B 100 18 0.8 0.9 5
C 100 19 2.0 1.4 7.6
D 119 20 2.9 1.7 8.5 NA NA
E 9052 18 10.2 3.2 17.0
Cefuroxime A 100 22 0.1 0.3 1.5
B 100 24 0.8 0.9 3.8
C 100 24 1.0 1.0 4
D 118 24 2.3 1.5 6.2 20–26 23
E 4774 25 6.8 2.6 10.4
Cefoxitin A 100 25 0.3 0.5 2.1 A 100 26 0.8 0.9 3.5
B 100 26 0.8 0.9 3.6 B 100 26 1.0 1.0 4.0
C 100 27 0.8 0.9 3.6 C 100 27 1.2 1.1 4.2
D 119 26 3.6 1.9 7.2 23–29 26 D 200 26 2.3 1.5 5.6 24–30 27














Ceftazidime A 100 24 0 0 0 A 100 24 0.2 0.4 1.8
B 100 26 0.8 0.9 3.2 B 100 24 1.1 1.0 4.3
C 100 27 1.2 1.1 4.1 C 100 25 0.7 0.8 3.3
D 118 26 1.7 1.3 4.9 23–29 26 D 133 23 1.6 1.3 5.5 21–27 24
E 4772 28 7.8 2.8 10.3 E 2867 23 12.0 3.5 15.0
Cefpodoxime A 100 23 0.8 0.9 4.2
B 100 24 1.0 1.0 4.2
C 100 25 1.4 1.2 4.8
D 116 25 2.3 1.5 6 23–28 26
E 4785 27 10.9 3.3 12.1
Ceftriaxone A 100 29 0.5 0.7 2.5
B 100 30 1.2 1.1 3.8
C 100 31 2.3 1.5 4.7
D 115 30 1.4 1.2 4 29–35 32
E 4766 31 7.3 2.7 8.7
Cefotaxime A 100 28 0.0 0 0
B 100 28 1.2 1.1 3.8
C 100 29 1.4 1.2 4.3
D 118 28 1.7 1.3 4.8 25–31 28
E 4769 31 11.6 3.4 11.1
Cefepime A 100 31 0.4 0.6 1.8 A 100 29 0.3 0.5 1.7
B 100 33 1.2 1.1 3.2 B 100 29 1.3 1.2 4.0
C 100 33 2.0 1.4 4.1 C 100 29 1.1 1.0 3.5
D 120 32 1.7 1.3 4.1 31–37 34 D 134 28 2.1 1.4 5.3 24–30 27
E 4726 32 9.6 3.1 9.6 E 2744 25 13.5 3.7 14.8
Ertapenem A 100 31 0.04 0.2 0.8
B 100 31 1.2 1.1 3.4
C 100 33 2.3 1.5 4.5
D 111 33 5.3 2.3 6.9 29–36 33
E 4484 33 10.9 3.3 10.1
Meropenem A 100 34 0.3 0.5 1.4 A 100 33 0.4 0.6 1.9
B 100 35 2.6 1.6 4.6 B 100 30 1.9 1.4 4.5
C 100 36 1.7 1.3 3.6 C 100 32 2.4 1.6 4.9
D 113 31 3.2 1.8 5.8 28–34 31 D 134 30 2.6 1.6 5.4 27–33 30
E 4628 33 10.2 3.2 9.7 E 2395 31 14.3 3.8 12.2
Imipenem A 100 28 0.8 0.9 3.1 A 100 27 0.1 0.3 1.1
B 100 32 2.3 1.5 4.6 B 100 26 4.0 2.0 7.6
C 100 33 2.0 1.4 4.2 C 100 25 2.6 1.6 6.3
D 108 30 2.3 1.5 4.8 26–32 29 D 134 24.5 2.3 1.5 6.2 20–28 24
E 4737 30 9.6 3.1 10.2 E 2582 27 13.0 3.6 13.1
Vancomycin A 100 16 0 0.2 1.1
B 100 16 0.5 0.7 4.5
C 100 17 0.6 0.8 4.7
D 112 15 0.5 0.7 4.7 10–16 13





























































































































































































































































































































































































Nalidixic acid A 100 28 0.1 0.3 1.1
B 100 27 1.0 1.0 3.6
C 100 28 2.0 1.4 4.9
D 117 26 2.3 1.5 5.9 22–28 25
E 6981 26 5.3 2.3 9.1
Norfloxacin A 100 34 0.1 0.3 1 A 100 23 0.5 0.7 3.2
B 100 32 0.8 0.9 2.8 B 100 24 0.8 0.9 3.9
C 100 32 2.0 1.4 4.2 C 100 24 0.5 0.7 2.9
D 111 31 4.8 2.2 7 28–35 32 D 107 22 1.4 1.2 5.2 18–24 21
E 6361 32 12.3 3.5 10.7 E 2630 24 7.8 2.8 11.4
Ciprofloxacin A 100 37 0.2 0.4 1.2 A 100 27 0.04 0.2 0.7 A 100 21 0.2 0.4 1.9 A 100 35 0.2 0.4 1.1
B 100 34 1.4 1.2 3.5 B 100 25 1.7 1.3 5.1 B 100 22 1.2 1.1 4.9 B 100 33 1.1 1 3.2
C 100 35 2.9 1.7 4.8 C 100 26 1.2 1.1 4.2 C 100 24 1.1 1 4.4 C 100 33 0.8 0.9 2.8
D 115 32 4.8 2.2 7 30–40 35 D 145 25 3.6 1.9 7.5 21–27 24 D 79 23 2.6 1.6 7.0 19–25 22 D 134 31 3.4 1.8 5.9 25–33 29
E 6230 33 11.6 3.4 10.1 E 2451 27 6.3 2.5 9.5 E 1523 23 5.2 2.3 10.1 E 2427 32 13.5 3.7 11.5
Levofloxacin A 100 35 0.4 0.6 1.6 A 100 28 0.5 0.7 2.6 A 100 22 0.1 0.3 1.2 A 100 28 0.2 0.5 1.7
B 100 34 1.0 1.0 2.9 B 100 28 1.7 1.3 4.6 B 100 22 0.5 0.7 3.3 B 100 26 1 1 3.8
C 100 33 1.7 1.3 3.8 C 100 29 1.4 1.2 4.2 C 100 24 1.1 1 4.3 C 100 27 0.8 0.9 3.4
D 117 32 6.8 2.6 8.3 29–37 33 D 200 27 2.3 1.5 5.5 23–29 26 D 110 22 2.7 1.6 7.6 19–25 22 D 134 25 3 1.7 6.8 19–26 23
E 6603 32 12.3 3.5 10.5 E 2628 28 6.3 2.5 8.9 E 2320 22 4.8 2.2 9.8 E 2495 28 16.4 4.0 14.4
Gentamicin A 100 23 0.3 0.5 1.9 A 100 22 0.2 0.4 1.6 A 100 18 0.2 0.5 2.7 A 100 20 0 0 0
B 100 24 0.5 0.7 2.9 B 100 22 0.8 0.9 4.2 B 100 17 0.7 0.9 5.0 B 100 20 0.6 0.8 3.8
C 100 24 1.2 1.1 4.7 C 100 24 1.0 1.0 4.3 C 100 18 0.5 0.7 4.1 C 100 22 0.9 0.9 4.4
D 116 23 3.2 1.8 8 19–26 23 D 200 23 2.0 1.4 6.1 19–25 22 D 112 16 1.8 1.3 8.6 12–18 15 D 134 20 2.9 1.7 8.1 17–23 20
E 9436 23 4.4 2.1 9.1 E 7058 23 5.3 2.3 9.9 E 2350 17 7.6 2.8 16.7 E 2880 20 10.9 3.3 15.9
Tobramycin A 100 21 0.4 0.6 2.8 A 100 21 0.3 0.5 2.1 A 100 20 0.2 0.5 2.2
B 100 21 0.8 0.9 4.2 B 100 22 1.2 1.1 5.0 B 100 21 1.0 1.0 4.6
C 100 22 1.0 1.0 4.3 C 100 23 0.8 0.9 3.7 C 100 23 0.8 0.9 3.9
D 120 23 1.7 1.3 5.7 18–26 22 D 199 22 2.0 1.4 6.2 20–26 23 D 134 23 1.8 1.4 6.0 20–26 23
E 9231 21 5.3 2.3 10.8 E 6936 22 5.3 2.3 10.2 E 2990 22 10.3 3.2 14.3
Amikacin A 100 24 0.2 0.4 1.9 A 100 23 0.3 0.5 2.0 A 100 24 0.1 0.3 1.2
B 100 23 0.6 0.8 3.6 B 100 22 0.8 0.9 4.0 B 100 23 1.0 1.0 4.3
C 100 24 1.4 1.2 4.8 C 100 23 0.8 0.9 3.8 C 100 24 1.8 1.3 5.5
D 117 23 3.6 1.9 8.2 19–26 23 D 150 22 2.0 1.4 6.6 18–24 21 D 134 24 2.5 1.6 6.7 18–26 22














Tetracycline A 100 25 0.0 0.2 0.8 A 100 30 1.0 1.0 3.3
B 100 25 0.6 0.8 3.2 B 100 24 1.4 1.2 5.3
C 100 26 0.8 0.9 3.5 C 100 29 1.2 1.1 3.8
D 117 22 2.6 1.6 7.5 NA NA D 141 27 2.9 1.7 6.1 23–31 27
E 6822 22 4.0 2 9.1 E 5036 28 6.3 2.5 8.9
Minocycline A 100 22 0.04 0.2 1.1 A 100 28 0.6 0.8 2.8
B 100 22 0.8 0.9 3.9 B 100 27 1.7 1.3 5.0
C 100 23 1.0 1.0 4.4 C 100 29 1.4 1.2 4.3
D 117 22 2.3 1.5 6.9 NA NA D 196 27 3.2 1.8 6.9 23–29 26
E 6934 22 6.8 2.6 12.1 E 4900 28 7.8 2.8 10.0
Tigecycline A 100 24 0.04 0.2 0.9
B 100 22 0.8 0.9 4.3
C 100 23 0.5 0.7 3.2
D 198 22 2.3 1.5 6.9 19–25 22
E 4910 23 5.3 2.3 10.0
Trimethoprim/sulfamethoxazole A 100 27 0.3 0.5 1.9 A 100 29 0.2 0.4 1.5
B 100 26 1.2 1.1 4.1 B 100 27 1.0 1.0 3.8
C 100 26 1.4 1.2 4.6 C 100 28 1.2 1.1 4.0
D 117 26 2.6 1.6 6.1 23–29 26 D 197 28 2.3 1.5 5.5 29–32 29
E 1366 27 4.0 2.0 7.5 E 3288 27 6.3 2.5 9.1
Erythromycin A 100 25 0.2 0.4 1.7
B 100 27 1.4 1.2 4.4
C 100 25 0.8 0.9 3.7
D 143 26 2.9 1.7 6.5 23–29 26
E 6059 26 7.8 2.8 10.6
Clindamycin A 100 28 0.4 0.6 2.3
B 100 28 1.7 1.3 4.7
C 100 27 0.8 0.9 3.3
D 145 27 3.2 1.8 6.4 23–29 26
E 6709 27 8.4 2.9 10.8
Rifampicin A 100 34 0.6 0.8 2.2
B 99 34 1.0 1.0 3.0
C 100 34 1.0 1.0 2.8
D 201 32 2.3 1.5 4.6 30–36 33
E 6998 32 7.3 2.7 8.7
Linezolid A 100 23 1.2 1.1 5.0
B 100 28 2.0 1.4 4.9
C 100 24 1.4 1.2 4.8
D 199 23 3.2 1.8 7.9 21–27 24
E 3694 24 7.3 2.7 11.1
Average all drugs A 0.2 0.4 1.5 A 0.4 0.6 2.3 A 0.1 0.3 1.5 A 0.2 0.4 1.5
B 1.0 1.0 3.7 B 1.2 1.1 4.5 B 0.7 0.9 4.6 B 1.3 1.1 4.4
C 1.5 1.2 4.5 C 1.0 1.0 4.0 C 0.9 1.0 4.9 C 1.2 1.1 4.2
D 2.8 1.7 6.5 D 2.4 1.5 6.3 D 1.8 1.3 7.2 D 2.4 1.6 6.2






































36.5% for S. aureus and E. coli versus 82.7% for P. aeruginosa
and 0% for E. faecalis. The highest biological contribution was
calculated for WT E. faecalis, vancomycin and gentamicin (high-
load disc) (98.8% and 91.9%, respectively; Table 2) and for
penicillinase-producing S. aureus and penicillin G (96%). For fluor-
oquinolones and S. aureus, the contribution of biological factors to
total variation decreased with increasing potency/generation of
the drug (70.6%, 40.7% and 28.0% for norfloxacin, ciprofloxacin
and levofloxacin, respectively; Table 2).
The contribution of measurement imprecision from auto-
mated zone diameter readings to total population zone diameter
variation was low, on average ranging from 1.5% to 5.3% for all
drug–species combinations (Table 2). Exceptions were seen in
S. aureus and cefoxitin, the fluoroquinolones and erythromycin
(relative contribution of 9.5%, 11.1% and 21.2%, respectively).
The average contribution of materials, e.g. lot variations in
antibiotic discs and Mueller–Hinton agar plates, to total variation
ranged from 2.4% to 3.9% for the tested species. Material-related
variations were above average for certain drug–species combina-
tions, e.g. proportions of .10% were found for E. coli, imipenem,
ceftriaxone and cefepime (10.4%–18.3%). In contrast, no contri-
bution of material-related variations was observed for E. coli and
penicillins, fluoroquinolones, aminoglycosides and tetracyclines
(0%). For P. aeruginosa, the impact of material variations was par-
ticularly high for the carbapenems (imipenem 28.8%).
Overall, manual inoculum preparation and operator-
dependent plate streakingwere themost important technical fac-
tors contributing to diameter measurement variation, ranging
from 6.8% to 24.8% and from 6.6% to 24.3%, respectively
(Table 2).
Both factors exceeded the biological contribution and were the
main contributors to total variation for fluoroquinolones, amino-
glycosides and E. coli (average of 27.3% and 34.6%, and of 32.2%
and 40.2%, respectively; Table 2) and for fluoroquinolones and
E. faecalis (average of 50.5% and 47.6%; Table 2).
Discussion
Some authors have generally commented on the contribution of
technical parameters and biological variability to total AST
variation. However, systematic data on the contribution of individ-
ual method-dependent variables to AST variation are rare to non-
existent for both disc diffusion and microdilution methods.16 In
this study, a statistical model was constructed to allow separation
of the relative influences of technical parameters and biological
variation in disc diffusion AST.
Generally, the relative contribution of biological variation was
different for individual drug–species combinations, varying from
10.4% to 98.8% (Table 2). Of note, the biological contribution to
total diameter variations in P. aeruginosawas higher as compared
with the other species investigated (average of 81.3% versus
47.0%, 53.9% and 64.0% for E. faecalis, E. coli and S. aureus,
respectively; Table 2). This is reflected in the higher variance of
P. aeruginosa WT populations (Experiment E; Table 1), but equal
technical variation parameters for all species (Experiment D;
Table 1). These results underline the particularly high variability
of AST data in P. aeruginosa populations due to intrinsic biological
traits affecting various classes of antimicrobials.17,18
The relative contribution of biological factors to total diameter
variation of bacterial populations may also reflect the relative
number of determinants contributing to innate drug susceptibil-
ity. This is exemplified by the fluoroquinolones and S. aureus:
less potent drugs such as norfloxacin are presumably affected
by a variety of comparably weak, unspecific and regulated
mechanisms, such as efflux pumps, that are present in the WT
(‘genetic background’).19 Clinical resistance to the more potent
drugs, such as ciprofloxacin and levofloxacin, requires mutations
in gyrA/parC, which are absent in the WT.20 Since a large number
of mechanismsmay affect innate drug susceptibility levels for the
weaker drugs, the relative biological variance may be higher. This
hypothesis is paradigmatically reflected in the decreasing relative
contribution of biological factors for norfloxacin, ciprofloxacin and
levofloxacin and the S. aureus WT (70.6%, 40.7% and 28.0%,
respectively; Table 2), reflecting different drug potencies in
increasing order.
Three principal settings exist considering the relation of tech-
nical and biological variability of zone diameter measurements:
(i) Lower biological variability, higher technical variability. In this
setting, it can be desirable to improve precision and reprodu-









































































6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
A 100 0 0 0 0 0 0 0 0 0 0 0 0 0 6 94 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 20 0.1 0.2 1.2
B 100 0 0 0 0 0 0 0 0 0 0 0 0 4 32 45 16 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 20 0.7 0.9 4.3
C 100 0 0 0 0 0 0 0 0 0 0 0 0 10 23 28 32 5 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 20 1.3 1.2 5.8
D 117 0 0 0 0 0 0 0 0 0 0 2 4 13 13 35 28 14 5 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 20 2.6 1.6 8.0
E 1389 0 0 0 0 0 0 0 0 68 99 134 208 391 512 710 710 716 601 430 287 152 82 46 17 0 0 0 0 0 0 0 0 0 0 0 21 8.0 2.8 13.4
Figure 2. Diameter distributions and related summary statistics for Experiments A–E exemplified by E. coli and ampicillin. Colours reflect the relative




Table 2. Relative contribution (%) of individual variation factors to total species WT zone diameter variance
Drug class Drug





























































































































































































































































Penicillins penicillin Ga 0.3 2.9 0.0 0.8 96.0
ampicillin 0.1 11.6 13.3 20.9 54.1 0.7 0.0 15.3 19.7 64.2
amoxicillin/clavulanic acid 4.0 0.0 16.7 20.0 59.3
piperacillin/tazobactam 0.1 0.0 18.0 21.1 60.8 2.8 0.0 8.6 8.7 79.8
Cephalosporins cefalotin 0.0 0.0 8.4 19.9 71.7
cefuroxime 1.5 0.0 16.5 18.3 63.7
cefoxitin 9.5 0.0 10.5 13.1 66.9 2.9 0.0 28.8 27.9 40.4
ceftazidime 0.0 7.6 2.5 5.6 84.4 1.4 0.0 8.1 4.7 85.7
cefpodoxime 0.0 4.3 4.7 10.6 80.3
ceftriaxone 6.5 18.3 0.0 1.6 73.5
cefotaxime 7.7 0.0 7.9 11.4 73.0
cefepime 3.3 10.4 0.0 5.7 80.6 1.8 0.9 7.0 5.0 85.2
Carbapenems ertapenem 0.5 0.0 22.6 30.6 46.3
meropenem 2.2 8.1 15.5 6.5 67.7 2.7 5.8 4.6 8.4 78.4
imipenem 8.3 14.0 1.4 0.0 76.4 0.5 28.8 0.0 0.0 70.6
average b-lactams 4.9 1.5 5.3 6.9 81.4 2.7 4.5 11.3 14.2 67.3 1.9 7.1 5.7 5.4 80.0
Glycopeptides vancomycin 0.8 0.4 0.0 0.0 98.8
Fluoroquinolones nalidixic acid 1.5 0.0 37.1 51.0 10.4
norfloxacin 14.6 0.0 10.2 4.6 70.6 1.2 0.0 30.1 39.6 29.1
ciprofloxacin 11.4 0.0 26.0 22.0 40.7 1.5 0.0 50.2 48.4 0 1.9 0.0 32.8 36.6 28.6 1.1 0.0 9.1 7.3 82.5
levofloxacin 7.6 0.0 33.8 30.6 28.0 2.5 0.0 50.7 46.8 0 1.5 0.0 37.1 51.0 10.4 1.3 0.0 8.4 7.4 82.9
average fluoroquinolones 11.1 0.0 22.0 17.6 49.3 2.0 0.0 50.5 47.6 0 1.7 0.0 27.3 34.6 36.5 1.2 0.0 8.7 7.4 82.7
Aminoglycosides gentamicin 3.6 0.0 12.5 12.5 71.3 0.4 7.6 0.0 0.1 91.9 3.3 0.0 34.0 47.4 15.3 0.0 0.0 6.0 8.9 85.0
tobramycin 0.2 3.9 3.4 5.5 87.0 5.0 0.0 34.1 35.7 25.1 2.0 0.0 10.9 7.9 79.3
amikacin 2.9 7.3 1.1 0.0 88.8 2.6 0.0 28.5 37.6 31.4 0.8 3.8 4.9 7.7 82.9
average aminoglycosides 2.2 3.7 5.7 6.0 82.4 3.6 0.0 32.2 40.2 23.9 0.9 1.3 7.3 8.2 82.4
Tetracyclines tetracycline 0.3 10.0 11.4 4.9 73.4 0.7 0.0 34.7 38.0 26.6
minocycline 2.8 0.6 7.2 10.8 78.7 0.8 0.0 17.2 21.4 60.7
tigecycline 5.2 0.0 47.9 46.8 0.0
average tetracyclines 2.8 5.0 29.7 25.9 36.7 0.8 0.0 25.9 29.7 43.6
Macrolides/Lincosamides erythromycin 21.2 0.0 16.3 12.7 49.8
clindamycin 0.5 0.0 26.2 22.9 50.4
Sulfa-drugs trimethoprim-sulfamethoxazole 0.5 18.8 2.2 0.0 78.4 1.6 0.0 26.3 25.7 46.4
Rifamycins rifampicin 2.6 0.0 16.4 10.5 70.5
Oxazolidinones linezolid 1.6 0.0 11.0 13.4 74.0
Average all drugs 5.3 2.7 14.8 13.2 64.0 1.5 2.4 24.8 24.3 47.0 2.4 2.6 18.4 22.6 53.9 1.4 3.9 6.8 6.6 81.3
aThe EUCAST S. aureus quality control strain ATCC 29213 harbours the blaZ b-lactamase. Biological variation thus does not reflect theWTas in all other drug-species combinations tested,
but the regulated penicillinase resistotype. Inhibition zone variability in the same genotype and the related variation in susceptibility categorization is very high due to regulation of gene
expression. Therefore, detection of the presence or absence of the regulated resistancemechanism is of critical importance. In the case of S. aureus and penicillin G, EUCAST recommends
screening for the presence of penicillinase by inspection of the inhibition zone edge. For other important resistance mechanisms, such as ESBL or plasmid-encoded ampC, data on the





































fluoroquinolones and the aminoglycosides in E. coli or the
fluoroquinolones in S. aureus (Table 2). Several drug species
combinations in this study illustrate specific technical chal-
lenges of the disc diffusion method. The influence of drug
stability on AST variability is illustrated e.g. by imipenem, a
relatively unstable compound, for which materials, such as
antibiotic discs, contributed 14% to total AST variation in
the P. aeruginosa ATCC WT strain (Table 2).21 The influence
of individual growth characteristics on AST variation is best
illustrated by S. aureus, cefoxitin, the fluoroquinolones or
erythromycin. Staphylococci produce rather fuzzy zone
edges that most likely contribute to the higher general read-
ing variation for S. aureus (5.3% versus 1.5%–2.4% for the
other species; Table 2). In particular, reading variation for
cefoxitin, the fluoroquinolones or erythromycin (all producing
fuzzy zone edges) was significantly higher (9.5%, 11.1% and
21.2%, respectively; Table 2) than reading variation for the
aminoglycosides (average of 2.2%), for which sharp zone
edges are usually observed.
(ii) Higher biological variability, lower technical variability. This
setting was observed for many drug–species combinations
in this study (Table 2). In such settings, practical conse-
quences differ for WT and non-WT populations:
(a) WTpopulations. If the biological contribution to AST vari-
ability is significantly higher than the technical contribu-
tion, the WTpopulation is assumed to be highly variable,
as was observed e.g. for P. aeruginosa in this study
(Table 2). As a consequence of such high intrinsic variabil-
ity, the risk of random susceptibility categorization
increases significantly if the WT population is split by a
CBP.6 CBPs equal to or lower than the ECOFF will reliably
prevent erratic categorization of the WT in settings with
higher biological variability and lower technical variability.
(b) Non-WT populations. If the biological contribution to
diameter variability is significantly higher than the tech-
nical contribution in a genetically homogeneous non-WT
population, CBPs should not split this population for the
same reasons that were outlined above for the WT.6
If, however, non-WTandWTpopulations overlap, CBP setting
cannot completely avoid splitting non-WTand/or WTpopula-
tions.22 In this case, screening for the presence or absence of
the corresponding resistance mechanisms is necessary to
prevent erroneous clinical categorization resulting from bio-
logical variation. For example, the EUCAST S. aureus quality
control strain ATCC 29213 is non-WT to penicillin G since it
harbours the regulated blaZ b-lactamase.9 The biological
contribution to total methodological variation is very high
(96.0%) due to high inhibition zone variability (ranging from
6 to 36 mm) for the same genotype (blaZ+, MRSA strains
were excluded). The EUCAST CBP for S. aureus and penicillin
is set at 26 mm, splitting this blaZ+ population. The detection
of the presence or absence of the regulated resistancemech-
anism (blaZ) is, however, of critical importance as an in vitro
penicillin G-susceptible blaZ+ S. aureus isolate may become
resistant in vivo due to up-regulation of gene expression.23
In the case of S. aureus and penicillin G, EUCAST thus recom-
mends screening for the presence of penicillinase by inspec-
tion of the inhibition zone edge for all isolates that display
inhibition zones in the susceptible range. Unfortunately,
data on the regulation of other important resistance
mechanisms, such as ESBL or plasmid-encoded ampC, are
widely lacking, and most likely biological variation necessi-
tates a requirement for detection of an ESBL, AmpC or carba-
penemase resistance mechanism similar to that described
above for S. aureus and blaZ.
(iii) If the relative contribution of technical and biological
variation is comparable, erroneous clinical categorization
depends equally on technical and biological factors.
Improving technical precision and detection of resistance
mechanisms—at least for the regulated and highly variable
ones—is necessary to improve the quality of AST reporting.
In summary, the higher the biological contribution to zone diam-
eter variability of a genetically homogeneous population, the
more important it is not to split this population into different clin-
ical categories and to determine the presence or absence of
resistance mechanisms, as otherwise erratic categorizations will
inevitably occur, even if measurements are technically very
precise and reproducible. The present work illustrates the species-
drug combination-specific biological contribution to zone diam-
eter variability. Thus, these datamay facilitate reliable CBP setting.
Furthermore, the present work illustrates the relative contribu-
tion of factors, such as inoculum preparation and operator skills,
that account for a significant part of technical variance in disc
diffusion AST. As technical imprecision contributes significantly
to AST classification errors, further improvement of AST precision
and reproducibility will affect the reliability of AST reports with
respect to the forecast probability of the predicted therapeutic
success or failure of individual drug–species combinations as
reflected in clinical AST categories (susceptible versus resist-
ant).6,14 The highest relative contribution to technical variation
originated from operator influence, i.e. mainly inter-operator
variations in plate streaking, followed by inoculum preparation
and materials. The laboratory cannot influence factors such as
the precision of disc charging or agar composition to improve cur-
rent AST. However, further standardization of operator influence
and inoculum preparation by mechanization and automation
could potentially increase the precision of disc diffusion AST, as
has previously been shown for zone diameter readings.5
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